Consequently, miR-21 expression regulated by Nanog/Stat-3 signaling pathway could be useful for the future drug target designs to treat HA/CD44-activated HNSCC (Figure 3). This evidence concerns the gene CD44 and head and neck squamous cell carcinoma.